ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,727.45
0.16%
US Tech 100
19,416.00
0.49%
다우존스 지수
42,131.70
0.02%
Bitcoin
63,675.81
0.55%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:REGN
일자시간출처헤드라인심볼기업
2024/09/2020:45GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/1401:15GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/1120:00GlobeNewswire Inc.EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety ProfileNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/1006:00GlobeNewswire Inc.Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/0920:00GlobeNewswire Inc.Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMONASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/09/0405:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/3005:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2905:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2620:00GlobeNewswire Inc.Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2614:00GlobeNewswire Inc.Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2107:45GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for LinvoseltamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2005:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/2005:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1606:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1600:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1505:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1505:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/1305:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0905:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0805:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0805:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0805:05GlobeNewswire Inc.Regeneron Announces Investor Conference Presentations and Oncology Investor WebcastNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0705:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:REGN

최근 히스토리

NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
COIN
AVAXUSD
Avalanche
NYSE
XOM
Exxon Mobil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
PM
XAUUSD
Gold vs US Dollar
COIN
ADAUSD
Cardano
NASDAQ
TSLA
Tesla
COIN
BTCUSD
Bitcoin
NYSE
AXP
American Express
COIN
ETHUSD
Ethereum
FX
USDJPY
US Dollar vs Yen
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유